GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (2)
  • Sun, Xiaolin  (2)
Material
Publisher
  • Wiley  (2)
Language
Years
Subjects(RVK)
  • 1
    In: International Journal of Rheumatic Diseases, Wiley, Vol. 24, No. 2 ( 2021-02), p. 268-273
    Abstract: The aim of this study was to identify the risk factors and prognosis of patients with cancer‐associated myositis (CAM). Method Four hundred and eighty‐seven patients with dermatomyositis (DM), clinical amyopathic dermatomyositis (CADM) and polymyositis (PM) from 3 clinical centers were enrolled retrospectively in this study. Clinical and laboratory data of CAM and non‐CAM patients were compared. Logistic regression analysis was used to identify risk factors of CAM. Results Out of the 487 patients with DM/CADM/PM, 7.0% (34/487) of patients were classified as CAM. Older age (53.91 ± 13.32 vs. 48.76 ± 14.34 years), heliotrope rash (61.8% vs. 41.9%), shawl sign (41.2% vs. 22.1%), V sign (58.8% vs. 38.6%) were observed significantly more commonly in patients with CAM than those without CAM (all P   〈  .05). Fever (17.7% vs. 37.8%), arthralgia/arthritis (23.5% vs. 45.7%), interstitial lung disease (ILD, 38.2% vs 68.9%) were significantly less common in the CAM group than the non‐CAM group. Age at onset (odds ratio [OR] 1.036, 95% CI 1.001‐1.072, P  = .042), shawl sign (OR 2.748, 95% CI 1.107‐6.822, P  = .029), anti‐transition initiation factor (TIF)‐1γ antibody (OR 4.012, 95% CI 1.268‐12.687, P  = .018) were identified as the initial risk factors for the onset of CAM, and ILD was identified as a protective factor for CAM (OR 0.292, 95% CI 0.115‐0.739, P  = .009). All‐cause mortality was significantly higher in CAM patients compared with non‐CAM patients ( P  = .001). Conclusion The mortality of patients with CAM was higher than DM/CADM/PM patients without cancer. Malignancy should be screened in DM/CADM/PM patients especially with risk factors, including older age, shawl sign, anti‐TIF‐1γ antibody, and lack of ILD.
    Type of Medium: Online Resource
    ISSN: 1756-1841 , 1756-185X
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2427877-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Immunology, Wiley, Vol. 168, No. 1 ( 2023-01), p. 184-197
    Abstract: Given increased acceptance of the CoronaVac, there is an unmet need to assess the safety and immunogenic changes of CoronaVac in patients with rheumatic diseases (RD). Here we comprehensively analysed humoral and cellular responses in patient with RD after a three‐dose immunization regimen of CoronaVac. RD patients with stable condition and/or low disease activity ( n  = 40) or healthy controls ( n  = 40) were assigned in a 1:1 ratio to receive CoronaVac (Sinovac). The prevalence of anti‐receptor binding domain (RBD) antibodies and neutralizing antibodies was similar between healthy control (HC) and RD patients after the second and the third vaccination. However, the titers of anti‐RBD IgG and neutralizing antibodies were significantly lower in RD patients compared to HCs ( p   〈  0.05), which was associated with an impaired T follicular helper (Tfh) cell response. Among RD patients, those who generated an antibody response displayed a significantly higher Tfh cells compared to those who failed after the first and the second vaccination ( p   〈  0.05). Interestingly, subjects with a negative serological response displayed a similar Tfh memory response to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐derived peptides as their anti‐RBD IgG positive counterpart, and all (4/4) of the non‐responders in HCs, and 62.5% (5/8) of the non‐responders in patients with RD displayed a positive serological response following the third dose. No serious adverse events were observed. In conclusion, our findings support SARS‐CoV‐2 vaccination in patients with RD with stable and/or low disease activity. The impaired ability in generating vaccine‐specific antibodies in patients with RD was associated with a reduction in Tfh cells induction. The window of vaccination times still needs to be explored in future studies. Clinical trial registration: This trial was registered with ChiCTR2100049138.
    Type of Medium: Online Resource
    ISSN: 0019-2805 , 1365-2567
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2006481-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...